SNPMiner Trials by Shray Alag


SNPMiner SNPMiner Trials (Home Page)


Report for SNP rs1062613

Developed by Shray Alag, 2020.
SNP Clinical Trial Gene

There is one clinical trial.

Clinical Trials


1 Effect of Genetic Association With Functional Dyspepsia and Mood Disorders

Background: Functional dyspepsia (FD) is one of the commonest digestive disorders. The pathophysiology of functional dyspepsia is uncertain. Risk factors include genetics, gender, age, helicobacter pylori infection, etc. However, few reported the association of genetic contribution to the development of FD and mood disorder. Indication: Functional dyspepsia patients Study center(s): Prince of Wales Hospital, Hong Kong Aims: - To evaluate genetic factors on development of functional dyspepsia & common mood disorders - To evaluate genetic factors on the severity of function dyspepsia & mood disorders - To develop a diagnostic test for classification of functional dyspepsia by plasma ghrelin and serotonin expression - To collect sleep data for future use - To save blood sample for future retrospective diagnostic or genetic examination Study design: Case-control cross sectional study Number of subjects: Total of 1200 subjects (300 FD patients + 300 relatives of FD patients FDR) and (300 Controls + 300 FDR) Patient population: Functional dyspepsia patients age 18-60 Duration of study: 1 May 2012 - 30 April 2013 Primary variable(s): Genetic polymorphisms of targeted genes, plasma ghrelin and serotonin expression Secondary variable(s): FD global symptom assessment and symptom scores Number of visits: 1 Hypotheses: - Shared genetic factors contribute to the development of FD and common psychological disorders - FD patients contribute to suppression of plasma ghrelin and serotonin expression compared to healthy controls

NCT02282995 Dyspepsia
MeSH: Dyspepsia Mood Disorders

High-throughput genotyping will be performed on the serotonin 3A receptor polymorphism (rs1062613) and ghrelin CLOCK 3111C polymorphism (rs1801260).

Primary Outcomes

Description: Differences of genetic polymorphism in targeted genes in patients with FD and mood

Measure: Differences of genetic polymorphism in targeted genes in patients with FD and mood disorders

Time: up to 48 months

Secondary Outcomes

Description: Diagnosis of psychiatric disorder with PHQ and HADS

Measure: Diagnosis of psychiatric disorder with PHQ and HADS

Time: up to 48 months

Description: Differences of plasma ghrelin and serotonin expression in FD patients and study controls.

Measure: Differences of plasma ghrelin and serotonin expression in FD patients and study controls.

Time: up to 48 months

Description: Symptom scores

Measure: Symptom scores

Time: up to 48 months


HPO Nodes